cadralazine

Cadralazine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C02DB04 (WHO);
Identifiers
	IUPAC name Ethoxy-N'-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}carbohydrazide;
CAS Number	64241-34-5 ;
PubChem CID	2515;
ChemSpider	2420 ;
UNII	8T96I3U713;
ChEMBL	CHEMBL2106561 ;
Chemical and physical data
Formula	C12H21N5O3
Molar mass	283.33 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1 ;
	InChI InChI=1S/C12H21N5O3/c1-4-17(8-9(3)18)11-7-6-10(13-15-11)14-16-12(19)20-5-2/h6-7,9,18H,4-5,8H2,1-3H3,(H,13,14)(H,16,19) ; Key:QLTVVOATEHFXLT-UHFFFAOYSA-N ;
(what is this?) (verify)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/09/12 14:08:18」(JST)

An estimation method of the clearance for a one-compartment model of a single bolus intravenous injection by a single sampling.

Funatogawa T1, Funatogawa I.
Journal of biopharmaceutical statistics.J Biopharm Stat.2012;22(1):43-53. doi: 10.1080/10543406.2010.502983.
In clinical trials, sometimes only a single drug concentration can be measured from a patient, because of the burden on the patient. From a single concentration, we cannot generally obtain point estimates of each pharmacokinetic parameter in a patient. In this article, we propose a method to estimat
PMID 22204526

Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension.

Tomita S1, Takata M, Yasumoto K, Tomoda F, Ueno H, Inoue H.
Japanese heart journal.Jpn Heart J.1999 Jan;40(1):55-63.
To assess whether electrocardiographic variables are useful to detect the regression of left ventricular (LV) mass after long-term antihypertensive treatment, we related electrocardiographic voltages to echocardiographic variables before and after treatment with an ACE inhibitor, temocapril (TEM), o
PMID 10370397

The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.

Ueno H1, Takata M, Tomita S, Oh-hashi S, Yasumoto K, Inoue H.
Journal of cardiovascular pharmacology.J Cardiovasc Pharmacol.1997 Nov;30(5):643-8.
This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension. Furthermore, to e
PMID 9388047

Different Effects of Temocapril and Cadralazine on Electrocardiographic Voltages and Left Ventricular Mass in Patients with Essential Hypertension.